197235-74-8

Upstream product

• 100-39-0 benzyl bromide 
• 197235-72-6 (3R,4R,5S,6R)-2-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-5-((3aS,4R,6S,7R,7aR)-7-hydroxy-4-hydroxymethyl-2,2-dimethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-6-yloxy)-6-hydroxymethyl-tetrahydro-pyran-3,4-diol 
• 75795-58-3 4-O-(3,4-O-isopropylidene-β-D-galactopyranosyl)-D-glucopyranose 

Downstream Products

• 123170-18-3 benzyl O-(2,6-di-O-benzyl-β-D-galactopyranosyl)-(1<*>4)-3,6-di-O-benzyl-2-O-pivaloyl-β-D-glucopyranoside 
• 123170-26-3 Benzyl O-(2,6-di-O-benzyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-(1->4)-2-O-pivaloyl-3,6-di-O-benzyl-β-D-glucopyranoside 
• 59263-36-4 benzyl 3,6-di-O-benzyl-4-O-(2,6-di-O-benzyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-β-D-glucopyranoside 

Relevant academic research and scientific papers

Efficient synthesis of ganglioside GM2 for use in cancer vaccines

A target antigen for cancer immunotherapy, ganglioside GM2, is expressed on the cell surface of several human cancer types. An efficient chemical synthesis can now make available ample amounts of a structurally well-defined synthetic GM2, free of biological contaminants. This greatly facilitates the systematic construction of safe and efficient GM2 cancer vaccines.